• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics >Determination of Plasma Caspofungin Content Using Tandem Mass Spectrometry (LC=MS/MS): An Accurate, Precise, Selective and Sensitive Method
【24h】

Determination of Plasma Caspofungin Content Using Tandem Mass Spectrometry (LC=MS/MS): An Accurate, Precise, Selective and Sensitive Method

机译：使用串联质谱法测定血浆Caspofungin含量（LC = MS / MS）：精确，精确，选择性和敏感的方法

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Caspofungin (Figure 1) is a lipopeptide antifungal drug, It is a member of a new class of antifungals called the echinocandins. It works by inhibiting the enzyme β(1,3)CDC Glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the first inhibitor of fungal βC1,ti glucan synthesis to be approved by the FDA in 2001. Its currently approved therapeutic indications include the empirical therapy of presumed fungal infections in febrile, neutropenic adult patients and the treatment of invasive aspergillosis in adult patients whose disease is refractory to, or who are intolerant of, other antifungal agents (i.e., conventional or lipid formulations of amphotericin B and/or itraconazole). Additionally, the FDA approval includes indication for the treatment of candidemia and some specific Candida infections (intra-abdominal abscesses, peritonitis, pleural cavity infections and oesophagitis) and the approval includes indication for the treatment of general invasive candidiasis in adult patients. Healthcare professionals commonly refer to the "average 70 kg patient". This was a true approximation for Americans during the 1960s for the average 20-74 year old (male= 76 kg, female = 64kg) The average weight of Americans in 2002 had risen to 86 kg for men and 74 kg for women. In fact, over two-thirds of Americans are overweight (body mass index [BMI] ≥25 kg/m2), with one-third being obese [BMI ≥ti0 kg/m2], and 6% having morbid obesity [BMI ≥40 kg/m2]. Therefore, studies describing the pharmacokinetics of medications, including caspofungin, are needed since a significant proportion of Americans are overweight or obese.
机译：卡泊芬净（图1）是脂肽抗真菌的药物，它是一种新的抗真菌剂类称为棘白菌素中的一个成员。它通过抑制酶β（1,3）葡聚糖CDC合酶和因此干扰真菌细胞壁的完整性。卡泊芬净是真菌βC1的第1抑制剂，TI葡聚糖的合成由FDA批准于2001年，目前批准的治疗适应症包括在发热推定真菌感染，中性白细胞减少症的成年患者的经验治疗和侵袭性曲菌的成人患者，其治疗疾病是难治的，或谁不耐受，其他抗真菌剂（的即常规或脂质制剂的两性霉素B和/或伊曲康唑）。另外，该FDA批准包括用于念珠菌的治疗和一些特定的念珠菌感染（腹内脓肿，腹膜炎，胸膜腔感染和食管炎）和批准包括用于成人患者的治疗一般侵袭性念珠菌病的指示指示。医疗专业人士通常指的是“平均体重为70kg的患者”。这是美国人的真实逼近20世纪60年代期间的平均20-74岁（男性= 76公斤，女= 64公斤级），平均体重的美国人在2002年已经上升到86公斤，男子74公斤的女性。事实上，在美国人三分之二超重（身体质量指数[BMI]≥25公斤/平方米），以三分之一肥胖[BMI≥ti0公斤/平方米]，和6％的具有病态肥胖[BMI≥40公斤/平方米。因此，需要描述药物的药代动力学，包括卡泊芬净，因为研究的美国人显著比例是超重或肥胖。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号